Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to boost quality of life for brain disorder patients

NCT ID NCT05732285

Symptom relief Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a program that combines talk therapy, brain training, and healthy lifestyle advice is practical and helpful for people with conditions like mild traumatic brain injury, multiple sclerosis, long COVID, or mild cognitive impairment. Fifteen participants were enrolled to see if they could complete the program and if it improved their daily life and well-being. The goal was to gather feedback and measure community integration and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Sep 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with one of the following: Mild Trauma Brain injury (TBI), Multiple Sclerosis (MS), Long COVID, or Mild Cognitive Impairment (MCI) * MCI patients age older than 50 years old, all other diagnosis 21-65 years old and are receiving care through the Michigan medicine network * Participants that can provide consent or legally authorized representative who can provide consent on their behalf * Cognitive impairment ≥ 1.0 standard deviation below the test score normed for age and education in at least 2 cognitive domains (verbal learning and memory, processing speed, or visuospatial memory) Exclusion Criteria: * TBI participants symptomatic at rest (headache, dizziness, nausea, or vertigo) will be referred to primary care physician (PCP) * History of TBI (except for participants with TBI) * MS participants with recent relapse (1 month prior to enrollment) or on Intravenous or oral steroids * MCI participants with disease duration greater than 1 year * Patients with other neurosensory or neurodegenerative diseases * Diagnosed with COVID-19 (except for Long COVID group) * Psychiatric disorders other than mild to moderate anxiety and depression * Patients with severe depression or suicidal (ideation or plan) will be instructed to seek mental health, provided with resources and referred to patient's primary care provider * Diagnosed sleep disorders * Visual or auditory impairment, * Current or history of alcohol or substance abuse/dependence * Cognitive impairment less than 1.0 standard deviation below the test score normed for age and education in at least 2 cognitive domains (verbal learning and memory, processing speed, or visuospatial memory) * Cognitive impairment greater or equal to 1.0 standard deviation below the test score normed for age and education in 1 cognitive domain (verbal learning and memory, processing speed, or visuospatial memory) * Currently receiving CRT, CBT or Occupational therapy (OT) or another type of psychological therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive dysfunction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Brain Injuries, Traumatic cognitive disorder Cognitive Dysfunction long COVID-19 multiple sclerosis traumatic brain injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cognitive dysfunction Mild cognitive impairment Multiple sclerosis Neurocognitive disorders Traumatic brain injury

Contacts and locations

Locations

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.